Frontier Science collaborated with the Breast International Group (BIG) on the ALTTO and Neo-ALTTO trials. These trials were built on the results from the successful HERA trial and aimed to study the benefit of adding Lapatinib to Herceptin® in both adjuvant and neo-adjuvant treatment regimens for breast cancer.
Frontier Science was responsible for randomisation, various aspects of project management, data quality control and for statistical programming and analysis. These trials involved participation of breast cancer trials groups and independent sites around the world, including North America. Neo-ALTTO reported its primary analysis in The Lancet in 2012 and ALTTO in the Journal of Clinical Oncology in 2015. The trials have now completed their follow-up analyses and Frontier Science is collaborating in the write up of the 10 year follow-up results for both trials.
ALTTO & Neo-ALTTO PUBLICATIONS
NeoALTTO: European Journal of Cancer (EJC)
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)
Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.
The ALTTO Trial: Results of the Primary Analysis
An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.
The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy
Findings from this study confirm that patients who achieve pathological complete response after neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without pathological complete response.
The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer
An article in The Lancet reporting that dual inhibition of HER2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting.
